Abstract:Background: While reporting of adverse drug events (AE) and adverse drug reactions (ADR) following Chinese materia medica (CM) injection is becoming more common, the reporting quality is of concern. Methods: A checklist about the reporting quality of AE/ADR was set up, and the ADR/AE reporting of Herba Houttuyniae injection was chosen as an example. Electronic databases Chinese Journal Net (1994-2009) and Chinese Science and Technological Journal Net (VIP) (1989-2009) were searched for target literature. Results: Based on our search strategy, 210 articles were included, with 175 articles reporting single or several cases of ADR/AE following Herba Houttuyniae injection (type I report). There were seven reports from regional or national ADR monitoring centers (type II report), and 28 summary reports from a single hospital or medical center (type III report). All 210 papers mentioned "adverse effect,""safety" or related meaning words in their titles, but 199 articles did not have abstract. Patient demographic characteristics were not fully reported in these articles. In type I articles, only 97 cases (43.11%) mentioned whether patients had or did not have a history of allergies, whereas 128 cases (56.89%) in type II papers and 14 (50%) type III papers, did not mention allergic history of patients. Only three articles (3/210, 1.43%), all of them type I, mentioned the syndrome type in Chinese medicine. None of the papers gave clear indications of the type and grade of ADR/AE of patients. Most papers did not report details of the CM injection procedure, such as the drug company, product serial number, or the drug's validity period. Data about the occurrence time and management of ADR/AE was also inadequately reported. Conclusion and recommendations: The current reporting format of ADR/AE in clinical CM injections is not standardized. Much fundamental information of ADR/AE following CM injection is therefore missing. A standard reporting format for ADR should be developed, and should include the following: (1) a title mentioning adverse effects and safety; (2) a structured abstract including adequate information about the patient and the disease treated, the drug used, the specific ADR/AE, physician response to the ADR/AE, and result of management; (3) demographic characteristic of the patients (gender, age, etc.); (4) clinical characteristics of patients (disease, syndrome, etc); (5) allergic history of patients; (6) diagnosis and syndrome based on Chinese medicine theory; (7) detailed information about the CM intervention (the manufacturer of the drug, series number, valid dates, dosage, route of administration, menstruum, dripping speed, etc.); (8) concomitant drug use; (9) time and symptoms of ADR/AE; (10) type and grading of ADR/AE; (11) physiological systems affected by ADR/AE; (12) specific treatment and prognosis for ADR/AE; (13) evidence of the cause and effect of ADR/AE; and (14) any other possibility of ADR/AE. Also, a ADR/AE registration system should be established.

Effect of Medical Background Differences on Reports of Adverse Drug Reactions

Quality Analysis of the Adverse Drug Reactions Reports from Shanghai Healthcare Professionals

Analysis of a Pharmacist-Led Adverse Drug Event Management Model for Pharmacovigilance in an Academic Medical Center Hospital in China

Adverse Drug Reaction Reporting Quality among Different Health Professionals and the Contribution of Clinical Pharmacists: A Pilot Study

Study of Serious Adverse Drug Reactions Using FDA-approved Drug Labeling and MedDRA

Analysis on 115 Cases of ADR Reports in Our Hospital

Retrospective Analysis of ADR Cases Reported in 2006 in Shenzhen

A cross-sectional study: comparison of public perceptions of adverse drug reaction reporting and monitoring in eastern and western China

Knowledge, Attitude and Practice of Hospital Pharmacists in Central China Towards Adverse Drug Reaction Reporting: A Multicenter Cross‐Sectional Study

The Role of Pharmacists in ADR Monitoring Mode of "physician Reporting, Pharmacist Assisting"

Analysis of the Adverse Drug Reactions Reports of 139 Cases

Investigation on professional structure and expertise of staffs in five adverse drug reaction monitoring centres at provincial level

An Investigation of Pharmacovigilance and Reporting of Adverse Drug Reactions in Hospitals: a Cross-Sectional Study in China

Literature Analysis on Adverse Drug Reaction in China

Analysis on Adverse Drug Reactions in Our Hospital from 2008 to 2010

The severity of adverse drug reactions and their influencing factors based on the ADR monitoring center of Henan Province

Analysis on 342 Repors and Discssion about the Methods of Prevention with Adverse Drug Reactions/events

2008-2011 Adverse Drug Reaction Analysis of 490 Cases in Huadong Hospital

Improving reporting of adverse events and adverse drug reactions following injections of Chinese materia medica

Adverse Drug Reactions Induced by Traditional Chinese Medicines in Our Hospital: Analysis of 145 Cases

The Adverse Drug Reaction Monitoring in Hospitals